MedTrace Logo

Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin

NCT03283176 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-10-19

No results posted yet for this study

Summary

Use of Ribavirin could affect hematologic profile of the patients negatively. With advent of new antiviral therapy, the preexisting hematologic changes may alter or corrected after treatment. However, this point is still not properly studied.

Conditions

  • Liver Cirrhoses
  • Chronic Hepatitis c
  • Directly Acting Antivirals

Interventions

DIAGNOSTIC_TEST

Vitamin B12 and Folic Acid

Vitamin B12 and Folic Acid measurement by ELISA technique

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2019-03-01
Completion
2020-01-14

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03283176 on ClinicalTrials.gov